First-to-invent versus first-to-file: impact of the AIA

Tara Rachinsky, Clark Sullivan, Shubha Ghosh, David S. Resnick, Carlyn Burton, Mary Anne Armstrong, John P. Hanish, Alexandra Sklan

Research output: Contribution to journalArticlepeer-review

Abstract

On March 16, 2013, the USPTO switched from a 'first-to-invent' to a 'first-to-file' patent system. Under the 2011 America Invents Act, patents will be awarded to the first inventor to file a patent application as opposed to the date of invention. Now, over a year since the main provisions of the America Invents Act (AIA) came into effect, Pharmaceutical Patent Analyst has invited a selection of IP specialists and researchers from the US to discuss the implications of this new law and how it will affect future pharmaceutical and medical R&D. Interview conducted by Alexandra Sklan, Commissioning Editor.

Original languageEnglish (US)
Pages (from-to)353-359
Number of pages7
JournalPharmaceutical patent analyst
Volume3
Issue number4
DOIs
StatePublished - Jul 1 2014
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'First-to-invent versus first-to-file: impact of the AIA'. Together they form a unique fingerprint.

Cite this